Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study
Neuroendocrinology · 2023 · 113 (3) · 332-342
DOI: 10.1159/000526811 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Neuroendocrinology, online erschienen am 31.08.2022. Verfasst von Piero Ferolla und 16 weiteren Autor:innen. Beteiligte Einrichtung: Multidisciplinary NET Center, Umbria Regional Cancer Network, Perugia, Italy. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Carcinoid Tumor. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Introduction
Lanreotide autogel (LAN) and temozolomide (TMZ) are guidelines-recommended monotherapies for thoracic neuroendocrine tumors (carcinoids; T-NETs), but prospective data for both combined and monotherapies are lacking. ATLANT (NCT02698410) evaluated efficacy and safety of LAN/TMZ in progressive T-NETs.
Methods
ATLANT was a 12-month, Italian, phase 2, single-arm, open-label, multicenter pilot study. Eligible patients had unresectable, locally advanced/metastatic, well-/moderately differentiated T-NETs with radiological progression. Patients received subcutaneous LAN 120 mg every 28 days and oral TMZ 250 mg/day for 5 consecutive days every 28-day cycle. Main endpoints are disease control rate (DCR) at 9 months (primary; investigator-assessed), median progression-free survival (PFS), biomarkers, and safety.
Results
The number of patients was 40; 60% were male. Primary tumor site was lung (90%) and thymus (10%). Carcinoid type was typical (20.0%) and atypical (52.5%). DCR at 9 months was 35.0% (95% confidence interval (CI) 20.63–51.68; nonacceptability threshold ≤10%, p < 0.0001; not significantly above clinically relevant threshold ≥30%, p = 0.2968). DCR between 7.5 and 10.5 months (sensitivity analysis) was 45.0% (95% CI: 29.26–61.51) and clinically relevant (p = 0.0320 at ≥30% threshold). Median PFS was 37.1 (95% CI: 24.1–52.9) weeks. No association was observed between biomarker variations (chromogranin A, neuron-specific enolase, somatostatin receptor type-2, Ki-67, 6-O-methylguanine-DNA-methyl-transferase) and DCR or PFS. Most patients (97.5%) had treatment-emergent adverse events (TEAEs); 72.5% had treatment-related TEAEs. TEAEs were mainly grade 1/2. No unanticipated TEAEs were reported.
Conclusions
This study showed that the LAN/TMZ combination has promising efficacy in progressive T-NETs, and was well tolerated. Larger studies are warranted to support the clinical benefits of LAN/TMZ in patients with T-NETs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Multidisciplinary NET Center, Umbria Regional Cancer Network, Perugia, Italy.
- Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Medical Oncology, University of Brescia at ASST-Spedali Civili, Brescia, Italy.
- Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IRCCS, IEO, Milan, Italy.
- Department of Oncology, Medical Oncology, A.O.U. San Luigi Gonzaga, Turin, Italy.
- Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), "Dino Amadori", Meldola, Italy.
- Department of Oncology 2, A.O.U. Pisana, Santa Chiara Hospital, Pisa, Italy.
Zitieren
APA
Ferolla, P., Berruti, A., Spada, F., Brizzi, M. P., Ibrahim, T., Marconcini, R., Giuffrida, D., Amoroso, V., La Salvia, A., Vaccaro, V., Faggiano, A., Colao, A., Volante, M., Ghizzoni, S., Mazzanti, P., Houchard, A., & Fazio, N. (2023). Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study. Neuroendocrinology, 113(3), 332-342. https://doi.org/10.1159/000526811
Vancouver
Ferolla P, Berruti A, Spada F, Brizzi MP, Ibrahim T, Marconcini R, et al. Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study. Neuroendocrinology. 2023;113(3):332-342. doi:10.1159/000526811
BibTeX
@article{Ferolla2023,
author = {Ferolla, Piero and Berruti, Alfredo and Spada, Francesca and Brizzi, Maria Pia and Ibrahim, Toni and Marconcini, Riccardo and Giuffrida, Dario and Amoroso, Vito and La Salvia, Anna and Vaccaro, Vanja and Faggiano, Antongiulio and Colao, Annamaria and Volante, Marco and Ghizzoni, Simona and Mazzanti, Paola and Houchard, Aude and Fazio, Nicola},
title = {Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study},
journal = {Neuroendocrinology},
year = {2023},
volume = {113},
number = {3},
pages = {332--342},
doi = {10.1159/000526811}
}
EUVIMED